Synaptic Depression: The Missing Link between Aβ and Tau?
Aβ oligomers rev up glutamate release, depressing synapses for the long term. This instigates the pathological phosphorylation of tau.
ALL NEWS
6509 RESULTS
Sort By:
- Most Recent
- Most Commented
First Cognitive Signal that Tau Immunotherapy Works?
Topline results from a Phase 2 trial of semorinemab suggest the therapeutic antibody may have eased the cognitive downturn in people with mild to moderate Alzheimer’s disease.
Mirror, Mirror on the Wall, Who’s the Earliest of Them All?
Decades before tangles become rampant, the biomarker p-tau231 rises in both CSF and plasma. More surprising: neuroinflammation markers do, too.
Can Exercise Protect People Whose Plasma Tau Is Up?
Among old people with high total tau levels in plasma, cognition slid far less in those who are active than in their inactive peers. Could blood tests motivate at-risk people to exercise?
Flipping the Script: Could Myelin Degeneration Drive Amyloidosis?
Myelin breakdown in the Alzheimer’s brain is thought to be a consequence of plaques, but a new study in mice suggests it may be a cause.
Polygenic Scores Paint Microglia as Culprits in Alzheimer's
AD risk scores based on gene expression in microglia associate with having amyloid plaques, and a microglial genomic atlas displays how variants influence gene expression. Polygenic variation in neurons sways cognition.
Double Whammy: APP Uppsala Deletion Ups Aβ and Its Aggregation Propensity
Found in one Swedish family, this mutation speeds up plaque deposition by way of two different mechanisms, leading to disease onset as young as age 40.
ADAD and LOAD: At Cellular Level, They Are Not the Same
Single-nuclei expression analysis identified different cell clusters from people who carried autosomal-dominant Alzheimer’s mutations or risk variants for late-onset AD. Also, microglia RNA-Seq goes big.
Up-and-Coming Immunotherapies Target Aβ and Tau
Scientists are testing passive and active immunotherapies that take down pyroglutamate Aβ, and a combo Aβ/tau vaccine.
AL001 Boosts Progranulin. Does it Slow Frontotemporal Dementia?
In an open-label Phase 2 study, fluid biomarkers suggested the anti-sortilin antibody restored lysosomal function and reduced neuroinflammation in people with symptomatic FTD. Tantalizingly, participants worsened less than historical controls.
Flurry of Investigations Besets Aducanumab
In the wake of the controversial thumbs-up for Aduhelm, the U.S. federal government is probing not only aducanumab’s price and approval history, but also the FDA’s accelerated approval pathway in general.
Aduhelm Approval Reverberates Through Research
Scientists worry about trial recruitment and retention, and discuss whether upcoming trials should allow aducanumab as a background therapy.
Lecanemab Post Hoc: Is Continual Treatment Required for Cognitive Benefit?
Patients taken off the drug continue to outperform those who were never on it, and decline slows even more once treatment resumes. Cognition and plasma Aβ changes are consistent with disease-modifying effect.
Will Insurance Cover Aducanumab? Jury Is Out
While payers public and private are deliberating whether or not to cover this first-in-class drug, the health economics group ICER re-affirms its original conclusion that aducanumab is overpriced.
Seeking Real-World Data on Whether Aducanumab Works
Biogen sponsors an observational study on the drug’s effects; no word yet on the FDA-required Phase 4 trial. Meanwhile, researchers suggest other ways to test efficacy.
Current Filters
- Date Range : All x